ICON plc | Clinical Research Organisation (CRO) for Drug Development

Procedural and regulatory know-how for China biotechs in the EU

How to navigate European Medicines Agency registration and regulation.

Considerations for DTx clinical trials in CNS indications

Successful digital therapeutic clinical trials.

Navigating orphan drug development

From early phase to marketing authorisation.

Approaching the CAR T-cell therapy horizon

Clinical advancements expanding the potential of CAR T-cell therapies.

Featured Solutions

Early Clinical and Bioanalytical Solutions

Innovative early clinical solutions that will advance your drug development strategy.

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.�

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional outsourcing

ICON is the world's largest provider of FSP services.

Webinars

Financial Times: Decentralised Clinical Trials in Focus

26 September 2023. Register now.

Taking a proactive and holistic approach to diversity assessment and planning

10 October 2023. Register now.

Advances in oncological imaging: Tumour growth rate modelling and radiomics

12 October 2023. Register now.

Beyond the Token: Why your healthcare data and integration strategy matters

20 October 2023. Register now.

Artificial Intelligence at ICON

27 November 2023. Register now.

Why outsourcing pharmacovigilance makes sense at an affiliate level

30 November 2023. Register now.

ICON Insights

22 August 2023

Highlights from the revised Medicare Drug Price Negotiation program guidance

Explore revised guidance instructions related to the Medicare Price Negotiation program in this blog.

21 August 2023

CMS Medicare Part D Price Negotiations

In this blog find more about a current list of drugs likely to be selected for negotiation, with their same-in-class competitors.

16 August 2023

The new EMA guideline expectations

In this blog, discover more about the new EMA guideline on computerised systems and electronic data in clinical trials.

27 July 2023

Patient-centric best practices for improved diversity

In this blog, we share best practices for a more patient-centric approach to trials as discussed in our webinar to improve accessibility, inclusion and diversity.

26 July 2023

Disease surveillance in low- and middle-income countries

Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks.

24 July 2023

Best practices for KPI management in FSP partnerships

Learn more about the best practices for KPI creation and management in this blog.

21 July 2023

Disease surveillance and innovative vaccines

Learn about current approaches to disease surveillance and why they are important for the advancement of vaccine development in this blog.

19 June 2023

EU CTR: Practical experiences and lessons learned

EU CTR effective January 31, 2022, introducing new age for interventional clinical trial applications in EU and EEA. Read more about the practical experiences and lessons learned.

13 June 2023

Rare diseases and orphan drugs regulatory framework in Canada

This blog details initiatives that are being taken by the Government of Canada to promote a health care system that works for those with rare disorders.

Solutions

Sectors

Therapeutics

Insights

News & Events

About ICON

COVID-19 vaccines: Post-authorisation safety surveillance

Navigating the regulatory labyrinth of technology in decentralised clinical trials

EMA guideline on computerised systems and electronic data in clinical trials

Exploring partnership culture and its impact on outsourcing and operational strategy